Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1B1 | P15121 | 10/20 | 1.00 |
| ▸ | AKR1A1 | P14550 | 3/20 | 1.00 |
| ▸ | AKR1B10 | O60218 | 2/20 | 1.00 |
| ▸ | MAPT | P10636 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fidarestat SCHEMBL48827 | 1.00 | AKR1B1 (1.00) | AKR1B1AKR1A1AKR1B10MAPT | |
| (R,S)-Fidarestat SCHEMBL1219758 | 1.00 | AKR1B1 (1.00) | AKR1B1AKR1A1AKR1B10MAPT | |
| Fidarestat SCHEMBL29546775 | 1.00 | AKR1B1 (1.00) | AKR1B1AKR1A1AKR1B10MAPT | |
| (R,S)-Fidarestat SCHEMBL29941924 | 1.00 | AKR1B1 (1.00) | AKR1B1AKR1A1AKR1B10MAPT | |
| (R,S)-Fidarestat SCHEMBL2855039 | 1.00 | AKR1B1 (1.00) | AKR1B1AKR1A1AKR1B10MAPT | |
| SCHEMBL9250816 | 0.91 | AKR1B1 (0.83) | AKR1B1AKR1A1AKR1B10MAPT | |
| SCHEMBL8311471 | 0.91 | AKR1B1 (0.83) | AKR1B1AKR1A1AKR1B10MAPT | |
| SCHEMBL8311883 | 0.89 | AKR1B1 (0.81) | AKR1B1AKR1A1AKR1B10MAPT | |
| SCHEMBL9411779 | 0.89 | AKR1B1 (0.80) | AKR1B1AKR1A1AKR1B10MAPT | |
| SCHEMBL9411773 | 0.89 | AKR1B1 (0.80) | AKR1B1AKR1A1AKR1B10MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 2603 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4719592-A1 | BICYCLIC COMPOUNDS FOR KETOHEXOKINASE INHIBITION | Centennial Therapeutics, LLC (US) | 2026-04-08 | — | — | EP | claimed |
| EP-4695239-A1 | DISUBSTITUTED PYRIMIDINE COMPOUNDS FOR KETOHEXOKINASE INHIBITION | Centennial Therapeutics, LLC (US) | 2026-02-18 | — | — | EP | claimed |
| CN-119418767-A | BDNF/TrkB signal pathway expression characteristic-based method for optimizing nervous system disease drugs | 普百思生物科技(苏州)有限公司 | 2025-02-11 | — | — | CN | claimed |
| WO-2024249612-A1 | BICYCLIC COMPOUNDS FOR KETOHEXOKINASE INHIBITION | CENTENNIAL THERAPEUTICS, LLC (US) | 2024-12-05 | — | — | WO | claimed |
| CN-119020492-A | Application of aldose reductase as intervention target in reversing drug resistance of liver cancer system therapeutic drug or treating liver cancer | 北京清华长庚医院 | 2024-11-26 | — | — | CN | claimed |
| US-20240374693-A1 | TREATMENT AND DETECTION OF INHERITED NEUROPATHIES AND ASSOCIATED DISORDERS | UNIVERSITY OF ROCHESTER | 2024-11-14 | — | — | US | claimed |
| WO-2024216034-A1 | DISUBSTITUTED PYRIMIDINE COMPOUNDS FOR KETOHEXOKINASE INHIBITION | CENTENNIAL THERAPEUTICS, LLC (US) | 2024-10-17 | — | — | WO | claimed |
| US-12090142-B2 | Combination therapy for the treatment of cancer | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2024-09-17 | — | — | US | claimed |
| US-12083168-B2 | Treatment and detection of inherited neuropathies and associated disorders | UNIVERSITY OF MIAMI (US) | 2024-09-10 | — | — | US | claimed |
| WO-2024064147-A1 | TREATING CONGENITAL DISORDERS OF GLYCOSYLATION | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2024-03-28 | — | — | WO | claimed |
| US-20020077319-A1 | Combination of GABA agonists and aldose reductase inhibitors | ARMY, SECRETARY OF THE | 2002-06-20 | — | — | US | claimed |
| US-20020068740-A1 | Combination of aldose reductase inhibitors and antihypertensive agents for the treatment of diabetic complications | MYLARI BANAVARA L (US) | 2002-06-06 | — | — | US | claimed |
| WO-2002043763-A2 | COMBINATION OF GABA AGONISTS AND ALDOSE REDUCTASE INHIBITORS | PFIZER PRODUCTS INC. (US) | 2002-06-06 | — | — | WO | claimed |
| US-20020061918-A1 | Compositions and treatment for diabetic complications | MYLARI BANAVARA L (US) | 2002-05-23 | — | — | US | claimed |
| US-6380200-B1 | TREATMENT OF DIABETIC NEUROPATHY, DIABETIC NEPHROPATHY, DIABETIC RETINOPATHY, MYOCARDIAL INFARCTION, CATARACTS AND DIABETIC CARDIOMYOPATHY | PFIZER, INC. | 2002-04-30 | — | — | US | claimed |
| EP-1106184-A2 | Combination of aldose reductase inhibitors and selective serotonin reuptake inhibitors for the treatment of diabetic complications | Pfizer Products Inc. (US) | 2001-06-13 | — | — | EP | claimed |
| EP-1106210-A2 | Combination of aldose reductase inhibitors and antihypertensive agents for the treatment of diabetic complications | Pfizer Products Inc. (US) | 2001-06-13 | — | — | EP | claimed |
| EP-1064965-A2 | Combinations of aldose reductase inhibitors and selective cyclooxygenase-2 inhibitors | Pfizer Products Inc. (US) | 2001-01-03 | — | — | EP | claimed |
| EP-1064964-A2 | Compositions containing aldose reductase inhibitors and selective cyclooxygenase inhibitors for the treatment of diabetic complications | Pfizer Products Inc. (US) | 2001-01-03 | — | — | EP | claimed |
| EP-1064949-A2 | Compositions containing aldose reductase inhibitors and selective cyclooxygenase inhibitors for the treatment of diabetic complications | Pfizer Products Inc. (US) | 2001-01-03 | — | — | EP | claimed |